Evidence map›Paper›PMID 41886040›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Oliver C Kiss, Ivan Penuelas, Ana Rey, Zhi Yang, Nic Gillings, Ambi Pillai, Emiliano Cazzola, Raymond M Reilly, Carlotta Taddei, Jeff Liu and 15 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Oliver C KissInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. o.kiss@hzdr.de.ORCID 0000-0001-7431-0026
Ivan PenuelasUniversity Clinic of Navarra, Pamplona, Spain.
Ana ReyUniversidad de la Republica, Montevideo, Uruguay.
Zhi YangPeking University Cancer Hospital & Institute, Beijing, China.
Nic GillingsCopenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Ambi PillaiMolecular Group of Companies, Cochin, India.
Emiliano CazzolaIRCCS Sacro Cuore, Negrar, Italy.
Raymond M ReillyUniversity of Toronto, Toronto, Canada.
Carlotta TaddeiLife Molecular Imaging GmBH, Berlin, Germany.
Jeff LiuDepartment of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Michael van DamUniversity of California, Los Angeles, USA.
Shozo FurumotoTohoku University, Sendai, Japan.
Junbo ZhangBeijing Normal University, Beijing, China.
Emerson Soares BernardesNuclear and Energy Research Institute - IPEN, Sao Paulo, Brazil.
Filippo LodiIRCCS, Bologna, Italy.
Winnie Deuther-ConradHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany.
Ya-Yao HuangPrimo Biotechnology, Taipei, Taiwan.
Yohannes Jorge LageboUniversity of Addis Abeba, Addis Abeba, Ethiopia.
Fany P EkoumeGeneral Hospital & University of Yaoundé, Yaoundé, Cameroon.
Miguel A Avila-RodriguezNational Autonomous University of Mexico (UNAM), Mexico City, Mexico.
Beverley SummersSefako Makgatho Health Sciences University, Pretoria, South Africa.
Amal ElrefaeiIAEA and Atomic Energy Authority of Egypt, Cairo, Egypt.
Maria SalgueiroUniversity of Buenos Aires, Buenos Aires, Argentina.
Catarina F RamogidaSimon Fraser University & TRIUMF, Burnaby, Canada.
Peter J H ScottUniversity of Michigan, Ann Arbor, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. MAIN BODY: This selection of highlights provides commentary on 25 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacy

Identifiers

PMID41886040
PMCPMC13066035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.